Abstract. Human neuroglioma is one of the most common malignant intracranial tumors in neurosurgery, and accounts for more than 50% of all brain cancer cases. Thus, a clinically effective drug with which to treat neuroglioma is urgently required. Pseudolaric acid B (PAB), a diterpene acid isolated from the root and trunk bark of *Pseudolarix kaempferi* Gordon (*Pinaceae*), was found to inhibit cell growth in a variety of cancer cell lines, but to date the effect of PAB on neuroglioma remains unclear. MTT analysis confirmed that PAB inhibited neuroglioma A172 cell growth in a time- and dose-dependent manner. In addition, PAB influenced the aggregation of tubulin in A172 cells. Meanwhile following PAB treatment, a higher percentage of cells accumulated in the G2/M phase from 12 to 48 h, while at 36 h, cell cycle slippage into the G0/G1 phase, and at 48 h, slippage into the S phase was observed using flow cytometric analysis. Corresponding protein expression was consistent with the cell cycle alteration as detected by western blotting, and it was speculated that cell cycle slippage was related to reduced effectiveness of PAB which warrants further investigation. Meanwhile PAB induced cell death by regulating p38, ERK and JNK expression and activating the DNA damage response. Therefore, PAB plays an antitumor role in A172 cells, and may be a candidate drug for neuroglioma therapy.

Introduction

Pseudolaric acid B (PAB) is a diterpene acid isolated from the root and trunk bark of *Pseudolarix kaempferi* Gordon (*Pinaceae*), known as ‘Tu-Jin-Pi’ in Chinese. PAB has been used to treat dermatological fungal infections. PAB was found to exert potent inhibitory activity on cell growth in vitro in various tumor cell lines (1-6) through cell cycle arrest, apoptosis or autophagy. However, to date the role of PAB in neuroglial cells is not clear.

Human neuroglioma is one of the most common malignant intracranial tumors in neurosurgery, and accounts for more than 50% of all brain cancer cases, and is recently diagnosed in a younger population (7,8). The pathogenesis of neuroglioma is related to multiple processes affected by dozens of regulatory factors (9); however, our knowledge concerning the underlying factors regulating neuroglioma progression remains unknow, and clinically effective drugs to treat neuroglioma are urgently required.

The DNA damage response, caused by a variety of stimuli, arrests the cell cycle to allow damage repair or direct cell apoptosis (10). Apoptosis, as one type of antitumor mechanism, has been a focus of numerous studies for antitumor drug development (11,12). In mammalian cells, the MAPK pathway is involved in cell proliferation or cell death: stress-activated protein kinase/c-Jun-N-terminal kinase (Sapk/Jnk), p38 kinase and extracellular signal-regulated kinase (Erk) (13). Generally, Erk protein promotes inflammation, apoptosis, growth, differentiation, oncogenic transformation, while Jnk and p38 are implicated in growth, differentiation and development (14,15). Cell cycle arrest is important after eukaryotic normal cell cycle progression is affected. These regulatory pathways are commonly referred to as cell cycle checkpoints (16). Cells are arrested at cell cycle checkpoints temporarily to allow for: i) cellular damage to be repaired; ii) the dissipation of an exogenous cellular stress signal; or iii) the availability of essential growth factors, hormones or nutrients.

In the present study, we showed that PAB inhibited neuroglioma cell proliferation and cell migration through influencing tubulin aggregation. Meanwhile, PAB further

---

Correspondence to: Dr Jinghua Yu, Institute of Virology and AIDS Research, The First Hospital of Jilin University, Jilin University, 519 Dongming Zhu Street, Changchun, Jilin 130021, P.R. China

E-mail: yjh-0-2002@163.com

*Contributed equally

Key words: pseudolaric acid B, apoptosis, cell cycle arrest, neuroglioma
induced DNA damage response to induce cell cycle arrest and cell death, which may provide a strategy to increase the antitumor effect of PAB.

**Materials and methods**

**Materials.** PAB, which was purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China), was dissolved in dimethyl sulfoxide (DMSO) to make a stock solution. DMSO concentration was maintained at <0.01% in all the cell cultures, and did not exert any detectable effect on cell growth or cell death. Propidium iodide (PI), phalloidin-tetramethylrhodamine B isothiocyanate, Hoechst 33258, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). TRIzol reagent and SuperScript™ III RT-PCR kit were purchased from Invitrogen (Carlsbad, CA, USA). Power SYBR-Green PCR Master Mix was purchased from ABI (Vernon, CA, USA). The following mouse cyclin, CDK, and MAPK antibodies were used in the western blot analyses: anti-CDK6, anti-cyclin D (both from Santa Cruz Biotechnology, Inc.), anti-cyclin B1 from Cell Signaling Technology, Inc., anti-CDK1 (Boster Biological Technology Co., Ltd., Wuhan, China), anti-cyclin E1, anti-cyclin A2 (both from ProteinTech Group, Inc.), anti-CDK2 (Cell Signaling Technology, Inc., Danvers, MA, USA), anti-cyclin El, anti-cyclin A2 (both from ProteinTech Group, Chicago, IL, USA), anti-CDK6, anti-cyclin D (both from Cell Signaling Technology, Inc.), anti-CDK1 (Boster Biological Technology Co., Ltd., Wuhan, China), anti-cyclin B1 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), anti-JNK1 and 2, anti-MAPK14 (p38) (both from Boster Biological Technology Co., Ltd.), anti-ERK1/2 (ProteinTech Group), anti-histone H3 (Amersham Pharmacia Biotech, Piscataway, NJ, USA), anti-γ-h2ax (Cell Signaling Technology, Inc.), anti-actin, and alkaline phosphatase labeled-secondary antibodies (both obtained from Santa Cruz Biotechnology, Inc.).

**Cyclin E Real-time**

<table>
<thead>
<tr>
<th>Primer pair</th>
<th>Role</th>
<th>Forward sequence 5'-3'</th>
<th>Reverse sequence 5'-3'</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclin E</td>
<td>Real-time</td>
<td>TCAGGGTATCACGTGGTGCAGA</td>
<td>CAAATCCAAACTTGCTCTTG</td>
</tr>
<tr>
<td>CDK2</td>
<td>Real-time</td>
<td>CTCTGGGGCTCAATATTCCACAG</td>
<td>CCGGAAAGCTGGTCATCTCAGA</td>
</tr>
<tr>
<td>Cyclin A</td>
<td>Real-time</td>
<td>GCATGCACCGTCTCCTCTTT</td>
<td>CAGGGCTATCTCACGCTCTAT</td>
</tr>
<tr>
<td>CDK6</td>
<td>Real-time</td>
<td>GTGCAGGTGGTGGTTTGATG</td>
<td>TATCCCTTATGGTTCAGTGGG</td>
</tr>
<tr>
<td>Cyclin D</td>
<td>Real-time</td>
<td>CTACTACCGGCTACCGCTTC</td>
<td>TCCCTCTCTTCTTCTCTCTC</td>
</tr>
<tr>
<td>CDK1</td>
<td>Real-time</td>
<td>TCAAGTGGTACGGCTAGAAAAA</td>
<td>TAACCTGGAATCCTGCAATAGC</td>
</tr>
<tr>
<td>Cyclin B1</td>
<td>Real-time</td>
<td>TGCCCTCAACAAAGCACATGA</td>
<td>GCTGGTCACGGTGCTAATC</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Real-time</td>
<td>GCAATTCCATGGCACCGT</td>
<td>TGGCCCACTTTGATTGG</td>
</tr>
</tbody>
</table>

**Cell growth inhibition test.** Inhibition of cell growth was determined by MTT assay. A172 cells (1.0x10^4 cells/well) were seeded into 96-well culture plates (Nunc, Roskilde, Denmark). After 24 h of incubation, different concentrations of PAB were added to the plates, and 0 µM PAB was used as a control, and other doses as samples. Following incubation, cell growth was measured at different time points by addition of 20 µl MTT (5 mg/ml) at 37°C for 2 h, and DMSO (150 µl) was added to dissolve the formazan crystals. Absorbance was measured at 492 nm with an enzyme-linked immunosorbent assay plate reader (Bio-Rad, Hercules, CA, USA). The percentage of inhibition was calculated as follows:

\[
\text{Cell death (\%)} = \frac{A_{492\text{ (control)}} - A_{492\text{ (sample)}}}{A_{492\text{ (control)}}} \times 100\%
\]

**Microtubule aggregation by fluorescence staining.** A172 cells (5x10^3) were placed on a coverslip in a 6-well plate. After 24 h of cell culture, they were treated with 4 µM PAB for 24 or 48 h, and then washed with PBS, fixed in 3.7% formaldehyde, and then rinsed three times in 1X PBS. After rinsing, followed by one rinse in 1X PBS and then staining with 5 µg/ml Hoechst 33258 for 30 min. The intensity of red staining was measured by fluorescence microscopy at excitation wavelength 584 nm with emission filter 607 nm (Leica, Nusslich, Germany). Nuclear changes were observed by fluorescence microscopy at excitation wavelength 350 nm with emission filter 460 nm (Leica).

**Cell migration.** A172 cells were cultured for 24 h, and then a line was scratched randomly with a pipette tip. Lines with the same width were chosen, and the width was recorded at 0, 12, 24, 36 and 48 h after control medium or PAB treatment by phase contrast microscopy (Leica).

**Flow cytometric analysis of cell cycle distribution.** A172 cells were cultured for 24 h, and then collected at 0, 12, 24, 36 and 48 h after control medium or PAB treatment. Collected A172 cells (1.0x10^6) were harvested and rinsed with PBS. The cell pellets were fixed in 70% ethanol at 4°C overnight. After washing twice with PBS, the cells were stained with 1.0 ml of PI solution containing PI 50 mg/l, RNase A 1 g/l and 0.1% Triton X-100 in sodium citrate 3.8 mmol/l, followed

---

Table I. Primers for real-time PCR.

<table>
<thead>
<tr>
<th>Primer pair</th>
<th>Role</th>
<th>Forward sequence 5'-3'</th>
<th>Reverse sequence 5'-3'</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclin E</td>
<td>Real-time</td>
<td>TCAGGGTATCACGTGGTGCAGA</td>
<td>CAAATCCAAACTTGCTCTTG</td>
</tr>
<tr>
<td>CDK2</td>
<td>Real-time</td>
<td>CTCTGGGGCTCAATATTCCACAG</td>
<td>CCGGAAAGCTGGTCATCTCAGA</td>
</tr>
<tr>
<td>Cyclin A</td>
<td>Real-time</td>
<td>GCATGCACCGTCTCCTCTTT</td>
<td>CAGGGCTATCTCACGCTCTAT</td>
</tr>
<tr>
<td>CDK6</td>
<td>Real-time</td>
<td>GTGCAGGTGGTGGTTTGATG</td>
<td>TATCCCTTATGGTTCAGTGGG</td>
</tr>
<tr>
<td>Cyclin D</td>
<td>Real-time</td>
<td>CTACTACCGGCTACCGCTTC</td>
<td>TCCCTCTCTTCTTCTCTCTC</td>
</tr>
<tr>
<td>CDK1</td>
<td>Real-time</td>
<td>TCAAGTGGTACGGCTAGAAAAA</td>
<td>TAACCTGGAATCCTGCAATAGC</td>
</tr>
<tr>
<td>Cyclin B1</td>
<td>Real-time</td>
<td>TGCCCTCAACAAAGCACATGA</td>
<td>GCTGGTCACGGTGCTAATC</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Real-time</td>
<td>GCAATTCCATGGCACCGT</td>
<td>TGGCCCACTTTGATTGG</td>
</tr>
</tbody>
</table>
by incubation on ice in the dark for 30 min. The samples were analyzed by a FACScan flow cytometer (Becton-Dickinson, Franklin Lakes, NJ, USA).

Quantitative real-time PCR. RNA was extracted from cells treated with control medium and PAB using TRIzol reagent (Gibco-BRL, Rockville, MD, USA) and isolated as specified.
by the manufacturer. The RNA was treated with DNase (DNase I-RNase-Free; Ambion, Foster City, CA, USA) to remove any contaminating DNA; 200 ng of total RNA was reverse-transcribed with oligo-dT primers using the High Capacity cDNA RT kit (Applied Biosystems, Foster City, CA, USA) in a 20 µl cDNA reaction, as specified by the manufacturer. For quantitative PCR, the template cDNA was added to a 20 µl reaction with SYBR-Green PCR Master Mix (Applied Biosystems) and 0.2 µM of the primers was added (primers are listed in Table I). Amplification was carried out using an ABI PRISM 7000 for 40 cycles under the following conditions: initial denaturation at 95°C for 10 min, plus 40 cycles of 95°C for 15 sec, followed by 60°C for 1 min. The fold changes were calculated relative to GAPDH using the ΔΔCt method for target gene mRNA analysis.

Observation of morphologic changes by light microscopy. A172 cells (5x10^5 cells/well) were cultured into a 6-well plate for 12 h. Then, the cells were treated with 4 µM PAB and/or caffeine for 0, 12, 24, 36 and 48 h, and morphologic changes were observed by phase contrast microscopy (Leica).

Western blot analysis of protein expression. A172 cells (1x10^6) were cultured in a 25-ml culture bottle for the indicated time, and then were treated with 4 µM PAB for the indicated time. Both adherent and floating cells were collected and frozen at -80°C. Western blot analysis was performed for total proteins as described previously (5). Protein expression was detected using primary polyclonal antibody (1:1,000) followed by a corresponding AP-conjugated secondary antibody diluted 1:1,000. Proteins were visualized using NBT and BCIP.

Statistical analysis. All data represent at least three independent experiments, and are expressed as mean ± SD. P-values <0.001 were considered to represent statistically significant differences.

Results

Inhibitory effect of PAB on A172 cells. To detect the inhibitory effect of PAB on neuroglioma cell proliferation, MTT assay was carried out. PAB treatment had an inhibitory effect on the A172 cells in a time- and dose-dependent manner (Fig. 1). In addition, 4 µM PAB inhibited cell growth with an inhibitory ratio of 40% at 48 h, as found in previous studies (5,6). Thus, we chose 4 µM PAB in the following experiments.

PAB promotes the aggregation of microtubule fiber. PAB exerts its function by influencing microtubule fiber aggregation (17). We found that PAB treatment promoted the uneven aggregation of microtubule fibers with more obvious red staining, while control cells showed even aggregation of microtubule fibers (Fig. 2). Therefore, PAB influenced cell microtubule fiber to exert its function.

PAB inhibits cell migration. Tumor cells with a high ability for migration are difficult to treat. In the migration assay, we confirmed that A172 cells had a high migration ability since with increasing time the scratch wound line disappeared. Meanwhile, after PAB treatment, the scratch wound line that remained was wider than that of the control cells (Fig. 3). Therefore, A172 cells had a high ability of migration, and PAB inhibited the cell migration of these cells.

PAB induces G2/M cell cycle arrest. It was observed that from 12 h, PAB treatment induced obvious G2/M cell cycle arrest. At 24 h, in the control group, the percentage of cells in the G2/M phases was 3.70±1.47%, while after PAB treatment it was 45.82±0.64%; at 36 h in the control group, the percentage of cells was 2.97±1.10%, while after PAB treatment it was 64.83±4.27%; at 48 h in the control group the percentage of cells was 3.45±1.29%, while after PAB treatment it was 56.98±2.14% (Fig. 4A). Therefore, PAB induced G2/M arrest. In addition, at 24 h after PAB treatment the percentage of cells in the G0/G1 phase was 4.50±3.98%, while at 36 h after PAB treatment the percentage of G0/G1 cells was 8.39±1.46%, and
at 48 h after PAB treatment the percentage of S phase cells (34.65±2.82%) was increased compared to the PAB group at 36 h (26.77±3.36%). Therefore, PAB induced cell cycle slippage from G2/M into G0/G1 and then into S phase. To further investigate the mechanism underlying the effect on the cell cycle by PAB, cyclin B1 and CDK1 expression was detected owing to the fact that the cyclin B1/CDK1 complex regulates G2/M process. It was found that from 12 h, the expression of cyclin B1 was increased after PAB treatment compared to the control treatment, and the expression of CDK1 was increased from 24 h, while at 48 h, the expression of CDK1 and cyclin B1 after PAB treatment was not increased compared to the control treatment (Fig. 4B). Therefore, PAB by regulating cyclin B1/CDK1 complex expression induced cell cycle arrest at G2/M until 36 h, and at 48 h cyclin B1/CDK1 complex expression was consistent with the cell cycle slippage. To explain the expression alteration of the cyclin B1/CDK1 complex, the transcription of this complex was analyzed. It was found that the mRNA level of cyclin B1 in the PAB group was 5.39 times higher than that in the control group after a 12-h treatment (P<0.01), while at 48 h, there was no obvious difference. For CDK1, at 12 and 48 h after PAB treatment, there was no difference with the control treatment (Fig. 4C). Therefore, PAB regulated protein expression through different mechanisms, partly through the transcriptional level.

Meanwhile, the effect of PAB on S phase and G0/G1-related protein expression was observed. It was found that in regards to S phase-related proteins, PAB decreased the expression of cyclin E at 24 and 36 h after PAB treatment, but at 48 h PAB treatment increased the expression of cyclin E, and PAB decreased the expression of CDK2 from 12 to 36 h after PAB treatment, but at 48 h, PAB treatment had no effect on CDK2 expression (Fig. 5A), which was consistent with the slippage into S phase at 48 h after PAB treatment. However, PAB treatment had no effect on the expression of cyclin A from 12 to 48 h compared to control treatment (Fig. 5A), indicating that PAB regulated cell cycle progression, possibly independent of cyclin A expression. In addition, we also assessed the transcription of them to explain the alteration at the protein level, and we found that the mRNA level of CDK2 was decreased after PAB treatment at 12 h compared to the control treatment, and the mRNA level of cyclin E was increased after PAB treatment at 48 h compared to the control treatment, which could partly explain the alteration of CDK2 and cyclin E (Fig. 5C). For G0/G1-related protein expression, it was found that at 36 h after PAB treatment, the expression of cyclin D was increased, but at 48 h, the expression of cyclin D was decreased (Fig. 5B), which was consistent with the slippage into S phase at 36 h, and then into S phase at 48 h after PAB treatment. The expression of CDK6 was not affected when compared to the control treatment (Fig. 5B), indicating that PAB regulated cyclin D expression to regulate the activity of cyclin D and CDK6 complex. In addition, at 12 and 48 h, PAB did not affect the mRNA levels of cyclin D and CDK6 compared to the levels noted in the control treatment group (Fig. 5C). Therefore, PAB regulates protein expression, but not at the level of transcription.
PAB induces cell death through MAPK protein. To further confirm the mechanism underlying the inhibition of cell proliferation by PAB, in the present study we confirmed the effect of PAB on cell death. From morphologic analysis, it was found that from 12 h, compared to the control group, the cell number was decreased by PAB treatment. Meanwhile it was found that in the PAB treatment group, the number of floating cells was increased compared to the number noted in the control group, indicating that PAB induced cell death (Fig. 6A). Then, we further analyzed the mechanism of cell death, and it was confirmed that from 12 to 48 h, the expression levels of JNK and ERK were decreased by PAB treatment compared to these levels in the control treatment group, while the expression of p38 was increased by PAB (Fig. 6B). Therefore, by regulating the expression of MAPK, PAB induced cell death in the A172 cells.

Thus, the expression of γH2AX, which is the marker of DNA damage response, was determined. It was found that PAB treatment increased the expression of γH2AX at 12, 24, 36 and 48 h compared to the expression levels noted in the control treatment group (Fig. 7A). Then, we analyzed the effect of caffeine on the inhibitory ratio of PAB, and it was found that at 24 h, caffeine treatment decreased the inhibitory ratio from 35.90±5.67 to 26.38±2.52%, and at 48 h caffeine treatment decreased the inhibitory ratio from 44.12±3.56 to 21.79±1.89%. Therefore, PAB activated the DNA damage response to induce apoptosis (Fig. 7B). Subsequently, caffeine was used to inhibit the DNA damage response, and it was found that 2 mM caffeine treatment inhibited cell death induced by PAB at 24 h and 48 h compared to that noted in the PAB treatment group (Fig. 7C).

Discussion

Glioblastoma is the most common cancer of the brain and displays an increasing incidence. Despite major advances in the field, there is no curative therapy for glioblastoma, to date (18). Pseudolaric acid B (PAB), a diterpene acid isolated...
from the root and trunk bark of *Pseudolarix kaempferi* Gordon was found to exert antitumor effect on different cell lines (1-6), and in the present study we explored the role of PAB in glioblastoma.

Firstly, we found that PAB inhibited glioblastoma cell growth in a time- and dose-dependent manner, indicating that PAB had potential anti-glioblastoma function. Similar to the role of PAB in other cell lines (17,19,20), PAB mainly affected microtubule aggregation in glioblastoma to inhibit cancer cell growth. It has been reported that glioblastoma cell migration and invasion occur at multiple stages of cancer progression and are a clinical obstacle for therapy. Thus, suppression
of glioblastoma cell migration and invasion may provide an effective therapeutic strategy (21). The present study confirmed that PAB inhibited the migration of glioblastoma, which is another advantage of PAB in the course of antitumor therapy.

Cell cycle arrest is an important mechanism by which to inhibit cell growth. We found that from 12 h, PAB treatment obviously increased the percentage of cells in the G2/M phase compared to the percentage in the control treatment group, indicating that PAB had the ability to induce cell cycle arrest to inhibit cell growth. In addition, PAB treatment increased the expression of cyclin B1/CDK1 complex expression, which was consistent with the profile of G2/M arrest. Meanwhile, PAB treatment increased the mRNA level of cyclin B1 at 12 h, indicating that PAB affected cyclin B1 transcription to regulate protein expression, and PAB did not affect CDK1 transcription, indicating that PAB regulated protein expression through different mechanisms. Meanwhile it was noted that at 36 h after PAB treatment, the percentage of G0/G1 phase cells was increased compared to 24 h after PAB treatment, and at 48 h after PAB treatment, the percentage of S phase cells was increased compared to 36 h after PAB treatment, indicating that at 36 h, cell cycle slippage into G0/G1 occurred, and at 48 h cell cycle slippage into S occurred. Furthermore, expression levels of cell cycle-related G0/G1 and S phase proteins were observed, and it was found that at 36 h after PAB treatment, the expression of cyclin E and CDK2 was increased compared to levels in the control treatment group, which was consistent with the results of cell cycle slippage.

Cell death is another mechanism of inhibiting cell growth. In the present study, based on morphologic analysis, we found that PAB treatment promoted cell death with increasing time, and PAB treatment inhibited the expression of JNK and ERK, and increased the expression of p38 compared to levels in the control treatment group. Therefore, PAB regulated corresponding protein expression to induce cell death. Meanwhile DNA damage response is commonly activated to promote cell death. We found that PAB treatment increased the expression of γ-H2AX, which is the marker of DNA damage response. Therefore, PAB treatment activated the DNA damage response. In addition, caffeine was used by us to inhibit the DNA damage response. We found that caffeine reversed the effect of PAB to protect cells from cell death, and correspondingly to decrease the inhibitory ratio; thus PAB activated the DNA damage response to induce cell death, which provided a target to increase the antitumor effect of PAB. In conclusion, PAB is a candidate for anti-glioblastoma treatment.

Acknowledgements

The present study was supported by funding from the National Natural Science Foundation of China (no. 81301416), the Postdoctoral Scientific Foundation of China (nos. 2014MS61302 and 2015T80299), the Norman Bethune Program of Jilin University (no. 2015202), the Jilin Provincial Science and Technology Department (nos. 20140204004YY and 20160414025GH), and the Department of Human Resources and Social Security of Jilin Province (no. 2016014).

References